Caution in signing nondisclosure contracts  by Johnston, K.Wayne
EDITORIAL
Caution in signing nondisclosure contracts
K. Wayne Johnston, MD, FRCS(C), Toronto, Ontario, CanadaPhysicians are often asked to sign nondisclosure con-
tracts with companies when they become involved in re-
search protocols, consulting arrangements, and mentoring
roles. Before withdrawal of the Ancure device, relatively few
complications were widely reported. Did a nondisclosure
contract inhibit disclosure of these complications to the
scientific community and patients?
The Ancure device was withdrawn from the market on
June 16, 2003, after Guidant agreed to plead guilty to 10
federal felony counts and to pay $92 million for failing to
report problems with the device. The criminal complaint
alleged that since introduction of the product in 1999 the
company reported only 172 malfunctioning devices, al-
though 2628 incidents had been recorded. Presumably,
vascular surgeons and interventionalists reported these
problems to Guidant, with the assumption that the com-
pany would report them to the Food and Drug Adminis-
tration (FDA), as required by federal law.
I am concerned that these problems were not empha-
sized in the medical literature or in presentations at con-
tinuing medical education courses. Were surgeons and
interventionalists who were investigators or proctors for the
device prevented from informing the scientific community
of complications by nondisclosure contracts with the com-
pany? An example from a different company’s research
protocol suggests that this might be possible.
The following comments have been extracted from
correspondence between an experienced endovascular sur-
geon and a company that asked that surgeon to provide
training and mentoring for other surgeons in the deploy-
ment of aortic stent grafts. I received this documentation
several years ago when I was Editor in Chief of the Journal
of Vascular Surgery. At that time there were many ongoing
investigational studies, and this example was not related to
the Ancure device. However, it is relevant to raise the issue
that a similar contract might have infringed on the respon-
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tients and colleagues.
The contract in question, specified that
[the] “Consultant shall provide training and related
consulting services . . . for [The Company] related to its
. . . stent graft and catheter system.”
Of particular concern to the surgeon was the compa-
ny’s request to control the data.
“. . . any material, information, data and devices de-
veloped in the course of performing the activities de-
scribed in this Agreement . . . are or shall be the prop-
erty of [The Company] and shall be maintained in
confidence and not used by Consultant . . . except as
necessary to perform the activities described in this Agree-
ment or until the lapse of three years from the date of
expiration or cancellation of this Agreement” [boldface
added by the author].
When the surgeon questioned the inclusion of restric-
tions on the release of data for 3 years, as specified in the
contract, in subsequent correspondence the surgeon was
told by a senior company employee that
“I [the company negotiator] have been involved with
many agreements in . . . [many other specialties] . . . and
never have we been faced with a strong objection [to the
wording of the contract].”
Does this mean that most investigators do not read the
contracts they sign? Or do they fail to understand the legal
and ethical implications of the contracts? Specifically, do
they not understand that if the company fully controls the
data the information is not available to patients or their
surgical colleagues unless the company chooses to release
it? Or do they simply sign a contract for personal or
institutional financial benefit or prestige?
In further correspondence from the company, the sur-
geon was cautioned that
“Terms of these contracts are matter to be discussed
between yourselves and [The Company] exclusively”
[boldface added].
Does this imply that investigators should not seek legal
advice, inform the institutional review board of their insti-
tution, or consult the institutional or university research
management before signing a contract?
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Volume 39, Number 6 Johnston 1353The company position was that
“Our mutual role is to enhance quality of life, further
education and nothing else” [boldface added].
Physicians are often asked to sign contracts with com-
panies when they become involved in research protocols,
consulting arrangements, and mentoring roles to teach
other surgeons how to use a new device. While it is reason-
able for a company to expect the physician to keep the
proprietary information on a device confidential, is it ap-
propriate for a contract to ask the physician to keep the
results and complications secret from patients or col-
leagues?
If a contract prevents the physician from disclosing data
that he or she has learned by using a new device, conflict of
interest may develop. First, the primary ethic in the physi-
cian-patient relationship of putting the patient’s welfare
above physician interests may be breached. In clinical stud-
ies the patients volunteer to participate. In the consent
process the patients are informed that the technique and
perhaps the device are relatively new and not fully validated
by long-term follow-up. Patients anticipate that results of the
study, whether positive or negative, and complications,
should they occur, will be disclosed to them. Second, the
expectation that physicians should carry out research in an
unbiased way may be contravened. Third, clinicians expect tobe able to share the results with other physicians to advance
medical knowledge and thereby improve patient care.
In signing a restrictive contract with industry, the phy-
sician may be put in a conflict of interest, that is, a legal
obligation to maintain company secrets versus the obliga-
tion to share information that may benefit patients and
other physicians. A contract that requires the surgeon to
maintain proprietary secrets that advance the financial in-
terests of the company is reasonable; however, one that
prevents the surgeon from sharing results and complica-
tions with patients under his or her care and with colleagues
is inappropriate.
In my opinion, vascular surgeons reported the compli-
cations with the Ancure device to the company; however,
they were not widely discussed in the medical literature.
Was this the fault of medical editors or reviewers who chose
not to publish negative information, or did nondisclosure
contracts have an important role in limiting dissemination
of this information to the scientific community and indeed
to patients? In relationships with companies, contracts
should never prevent researchers from informing patients
and the scientific community of risks identified during a
clinical study.
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